These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Chen CH; Ji H; Suh KW; Choti MA; Pardoll DM; Wu TC Gene Ther; 1999 Dec; 6(12):1972-81. PubMed ID: 10637448 [TBL] [Abstract][Full Text] [Related]
25. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150. Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963 [TBL] [Abstract][Full Text] [Related]
26. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Cheung YK; Cheng SC; Sin FW; Xie Y Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183 [TBL] [Abstract][Full Text] [Related]
27. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses. Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864 [TBL] [Abstract][Full Text] [Related]
28. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182 [TBL] [Abstract][Full Text] [Related]
29. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine]. Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710 [TBL] [Abstract][Full Text] [Related]
30. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912 [TBL] [Abstract][Full Text] [Related]
31. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427 [TBL] [Abstract][Full Text] [Related]
32. MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model. Sin JI Vaccine; 2011 May; 29(24):4125-31. PubMed ID: 21496466 [TBL] [Abstract][Full Text] [Related]
33. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Lin CT; Tsai YC; He L; Yeh CN; Chang TC; Soong YK; Monie A; Hung CF; Lai CH Immunol Lett; 2007 Dec; 114(2):86-93. PubMed ID: 17976741 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. Wu TC Eur J Immunol; 2007 Feb; 37(2):310-4. PubMed ID: 17273998 [TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898 [TBL] [Abstract][Full Text] [Related]
36. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene. Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833 [TBL] [Abstract][Full Text] [Related]
37. A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. Hosseinzadeh S; Bolhassani A; Rafati S; Taheri T; Zahedifard F; Daemi A; Taslimi Y; Hashemi M; Memarnejadian A Drug Deliv; 2013; 20(3-4):190-8. PubMed ID: 23745741 [TBL] [Abstract][Full Text] [Related]
38. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer. Ajorloo M; Alamdary A; Soleimanjahi H; El Boulani A; Khanizadeh S; Nikoo HR Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722 [TBL] [Abstract][Full Text] [Related]
39. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
40. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice]. Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]